Cancer Research Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Howard, C. M.
Right arrow Articles by Giordano, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Howard, C. M.
Right arrow Articles by Giordano, A.
[Cancer Research 60, 2737-2744, May 15, 2000]
© 2000 American Association for Cancer Research

Tumor Biology

Inducible pRb2/p130 Expression and Growth-suppressive Mechanisms: Evidence of a pRb2/p130, p27Kip1, and Cyclin E Negative Feedback Regulatory Loop1

Candace M. Howard, Pier Paolo Claudio, Antonio De Luca, Peter Stiegler, Francesco Paolo Jori, Nabile M. Safdar, Mario Caputi, Kamel Khalili and Antonio Giordano2

Department of Pathology, Anatomy & Cell Biology, Jefferson Medical College, Philadelphia, Pennsylvania, 19107 [C. M. H., P. P. C., P. S., F. P. J., N. M. S., A. G.]; Department of Scienze Odontostomatologiche e Maxillo Facciali, Universita’ degli Studi di Napoli "Federico II", Naples, Italy [P. P. C.]; Laboratory for Cell Metabolism and Pharmacokinetics, Center for Experimental Research, Regina Elena Institute, 00158 Rome, Italy [A. D. L.]; Istituto di malattie dell’apparato respiratorio, II Universita’ degli Studi di Napoli, Istituto di Ricerca Cardio-Pneumologico A.O. "Monaldi," Napoli, Italy [M. C.]; and Center for NeuroVirology and NeuroOncology, MCP-Hahnemann University, Philadelphia, Pennsylvania 19102 [K. K.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 
The retinoblastoma family of proteins, pRb/p105, p107, and pRb2/p130, cooperate to regulate cell cycle progression through the G1 phase of the cell cycle. Each of the family members realize their common goal of G1-S checkpoint regulation through overlapping and unique growth regulatory pathways. We took advantage of a tetracycline-regulated gene expression system to control the expression of RB2/p130 in JC virus-induced hamster brain tumor cells to study in vivo the molecular mechanisms used by pRb2/p130 to elicit its growth-suppressive function. We have previously used this system to demonstrate that induction of pRb/p130 expression suppresses tumor growth in vivo by overcoming neoplastic transformation mediated by the large T-antigen oncoprotein of JCV (JCV TAg). Here we found that induction of pRb2/p130 in vivo specifically inhibits cyclin A- and cyclin E-associated kinase activity and by doing so induces p27Kip1 levels presumably by inhibiting p27Kip1-targeted proteolysis by cyclin E-Cdk2 phosphorylation of p27Kip1. RB2/p130 induction also decreased cyclin A and the transcription factor E2F-1 while increasing cyclin E at both the transcriptional and protein levels of expression. The growth inhibitory activity of pRb2/p130 also correlated with its E2F-binding capacity. Furthermore, p27Kip1 and pRb2/p130 were found to be targets of the JCV TAg oncoprotein and to interact in vivo with each other independently from the presence of TAg. Interestingly, pRb2/p130 expression negatively modulated the binding of p27Kip1 to JCV TAg. These data suggest that pRb2/p130 and p27Kip1 may cooperate in regulating cellular proliferation, and both may be involved in a negative feedback regulatory loop with cyclin E.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 
The Rb3 family of proteins, pRb/p105, p107, and pRb2/p130, are defined by a structural and functional domain known as the pocket region. They are highly homologous within the pocket region that is responsible for many of the important protein-protein interactions for their growth-suppressive functions. The pocket domain consists of A and B subdomains divided by a spacer region. Rb family members, p107 and pRb2/p130, form their own subfamily because of their similarity in the spacer region. Each of the Rb family members are nuclear phosphoproteins that regulate G1 progression, are implicated in various forms of differentiation, are regulated in a cell-cycle-dependent manner by phosphorylation, are growth-suppressive in a cell-type-dependent manner, and are critical targets for inactivation by transforming oncoproteins of DNA tumor viruses (1 , 2) .

Intriguingly, several lines of evidence indicate that the functional overlap between the proteins does not extend to complete redundancy. Each of the Rb family proteins binds to and modulates the activity of the E2F family of transcription factors that stimulate the transcription of genes needed to progress through the S phase. However, the timing of this regulation varies between Rb family members, and they each bind to distinct members of the E2F family (3) . pRb2/p130 in association with E2F-4 is the most abundant E2F complex found in resting or quiescent cells in G0, and this complex is thought to help maintain a state of transcriptional silence (4 , 5) . The pRb2/p130-E2F-4 complex negatively modulates the expression of the E2F-1 promoter linked to a CAT reporter system by a repressive E2F site in the promoter (6) . In this manner, pRb2/p130 also regulates the expression of the RB/p105 and p107 genes because each contains E2F sites in their promoters (7 , 8) . As the cells start to re-enter the cell cycle, E2F-4 is still found in association with pRb2/p130 in early G1. pRb2/p130 is then replaced by p107 in mid to late G1 and then by pRb/p105 in late G1 and S phases (5 , 9, 10, 11) . In vivo, only pRb/p105 is found in association with E2F family members E2F-1, E2F-2, and E2F-3 (12) . Both E2F4 and E2F-5 were cloned for their ability to associate with pRb2/p130 (9, 10, 11) .

Each of the Rb family proteins are negatively regulated by phosphorylation, which frees the E2F family of transcription factors to induce the transcription of genes whose protein products are necessary for S-phase progression. The phosphorylation status of each of the Rb family members varies throughout the cell cycle. Several cyclin-dependent kinases are implicated in this process (1) . The best candidates for phosphorylation of pRb/p105 and p107 are the cyclin D1-Cdk4/6 complexes (1 , 13) . In vitro studies indicate that cyclin D3-Cdk4 complexes are capable of using pRb2/p130 as a substrate. The timing of the activation of the cyclin D3-Cdk4 complex coincides with the phosphorylation profile of pRb2/p130. Furthermore, pRb2/p130 associates with cyclin D3 both in vitro and in vivo, making the cyclin D3-Cdk4 complex the best candidate for phosphorylation of pRb2/p130 (14) .

Opposed to pRb/p105, both p107 and pRb2/p130 form stable complexes with cyclin A-Cdk2 and cyclin E-Cdk2 complexes (15, 16, 17, 18, 19, 20) . The question of whether the cyclins are targeting these Rb family members for phosphorylation and functional inactivation or whether p107 and pRb2/p130 are modulating the function of these kinases is a complex issue. Interestingly, p107 and pRb2/p130 contain a p21-like kinase inhibitory domain that has been shown to inhibit Cdk2 kinase activity in vitro, in vivo for p107 (21 , 22) , and in vitro for pRb2/p130 (22 , 23) . Additionally, a distinct kinase inhibitory domain in pRb2/p130 is located in the spacer region that specifically inhibits Cdk2 kinase activity in vitro (23) .

Studies examining the growth-suppressive mechanisms used by the proteins reveal distinct differences. The growth-suppressive activity for the Rb family members is cell type-specific. Saos-2 cells, human osteosarcoma, are growth-arrested in the G0/G1 phase of the cell cycle by each of the Rb family members (20 , 24 , 25) . Certain cell lines, such as the C33A human cervical carcinoma cell line, are inhibited by overexpression of p107 (20) and pRb2/p130 (26) but not by pRb/p105. Furthermore, the T98G cell line, human glioblastoma, is sensitive to the growth-suppressive effects of pRb2/p130, yet refractory to that of family members pRb/p105 and p107 (24) . This suggests that there are at least some fundamental differences in the molecular pathways that the Rb family proteins influence to elicit cell cycle control.

To explore the in vivo effects of induction of pRb2/p130 expression on the cell cycle machinery, we used a modified tetracycline inducible expression system in hamster glioblastoma cells transformed by the JC virus (27) , the human polyoma virus that is the etiological agent of progressive multifocal leukoencephalopathy (28) . In this system, pRb2/p130 expression is repressed in the presence of tetracycline and induced upon the withdrawal of tetracycline from the cellular medium (27) . The JC virus contains a large TAg oncoprotein that is 72% homologous to its SV40 counterpart (28 , 29) and that effectively targets and functionally inactivates each of the Rb family members (27 , 30, 31, 32, 33) . Therefore, in the uninduced state, this system is essentially functionally null for each of the Rb family members. We have previously demonstrated that induction of pRb2/p130 in this system is able to overcome JCV TAg-mediated cellular transformation. Induction of pRb2/p130 expression results in nearly 90% of the cells growth-arrested in the G0/G1 phase of the cell cycle, and growth suppresses tumor formation both in vitro and in vivo (27) . RB2/p130 has recently been shown to be mutated and/or functionally inactivated in a number of tumor cell lines (34) and primary human tumors, including lung cancer, mesothelioma, nasopharyngeal carcinoma, and Burkitt’s lymphoma (35, 36, 37, 38, 39) . Restoration of RB2/p130 by way of viral-mediated gene delivery led not only to inhibition but actual regression of tumor formation in vivo (35) , thereby demonstrating that RB2/p130 behaves as a true tumor suppressor gene. In this paper, we examined in detail the molecular mechanisms involved in pRb2/p130-mediated growth suppression.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS AND DISCUSSION
 REFERENCES
 
Cell Lines.
The HJC{Delta}5 and HJC12 cell lines were described previously (27) . Briefly, the HJC{Delta}5 originated from the HJC-15c clonal cell line deriving from a JCV-induced hamster brain tumor, initially described in 1995 (40) . The HJC{Delta}5 cell line is a stable cell line containing the pTet-tTak plasmid (Life Technologies, Inc., Gaithersburg, MD) that expresses the tetracycline transactivator under the control of the Tetp in the absence of tetracycline. HJC{Delta}5 was the parental cell line of the HJC12 cells, which are stable clones containing the pTet-tTak and the UHD hyg BH-RB2/p130 plasmids, which contain the full-length cDNA of the human RB2/p130 gene downstream of the Tetp promoter (27 , 41) . The Tetp promoter is repressed in the presence of 2 µg/ml tetracycline in the media. Withdrawal of tetracycline from HJC12 cell media induces pRb2/p130 expression. Both HJC{Delta}5 and HJC12 cells were maintained in DMEM supplemented with 5% calf serum (Life Technologies, Inc., Gaithersburg, MD), antibiotics in the presence (not induced) or absence (induced) of 2 µg/ml tetracycline (Sigma, St. Louis, MO).

African green monkey kidney COS-7 cells (transformed by SV40) and human osteosarcoma SAOS-2 cells were purchased from the American Type Culture Collection (Manassas, VA) and maintained in DMEM supplemented with 10% fetal bovine serum and L-glutamine.

WB Analysis and Immunoprecipitation.
WBs and immunoprecipitations were performed as previously described (19) . Protein concentration was assayed by Bradford analysis (Bio-Rad Laboratories, Inc., Melvile, New York) and confirmed by running 5 µg of protein on a 10% SDS-PAGE and staining with Coomassie blue. Primary rabbit polyclonal anti-pRb2/p130 COOH antibody (ADL1, produced in our laboratory) was used at a dilution of 1:1000 in a solution of Tris-buffered saline + 0.5% Tween-20 and 5% dry milk for WB analysis and 5 µl each of 100 µg of protein for immunoprecipitation. The loading and transfer of equal amounts of protein were confirmed by staining the membranes with Red Ponceau (Sigma, St. Louis, MO). The specificity of the ADL1 antibody for recognizing pRb2/p130 in WB analysis and immunoprecipitation has been previously demonstrated (19 , 42) . The PAB 416 monoclonal antibody that cross-reacts with JCV and SV40 TAg (Cold Spring Harbor Facility, Cold Spring Harbor, NY) was used at a dilution of 1:10 for WB analysis and 100 µl each of 100 µg of protein for immunoprecipitation. The following primary rabbit polyclonal antibodies were used as follows: anti-p27Kip1 antibody was used at a dilution of 1:500 for WB analysis and 5 µl each of 100 µg of protein for immunoprecipitation; anti-cyclin A antibody was used at a dilution of 1:500 for WB analysis and 10 µl each of 100 µg of protein for immunoprecipitation; anticyclin E antibody (produced in our laboratory or Santa Cruz, CA) was used at a dilution of 1:250 for WB analysis and 10 µl each of 100 µg of protein for immunoprecipitation; anti-Cdk2 was used at a dilution of 1:500 for WB analysis and 10 µl each of 100 µg of protein for immunoprecipitation; anti-Cdk4 was used at a dilution of 1:250 for WB analysis; anti-E2F-1 (Santa Cruz, CA) was used at a dilution of 1:1000 for WB analysis; and anticyclin D1 and anticyclin D3 were used 10 µl each of 100 µg of protein for immunoprecipitation. The antibodies were produced in our laboratory unless stated otherwise.

Kinase Assays.
Cell lysates from HJC12 cells grown in the presence or the absence of 2 µg/ml tetracycline for 48 h were prepared by resuspending pelleted cells in 200 µl of lysis buffer (50 mM Tris, 5 mM EDTA, 250 mM NaCl, 50 mM NaF, 0.1% Triton, 0.1 mM NA3VO4, plus protease inhibitors). An equal amount of protein for each fraction was immunoprecipitated with a specific antibody. pRb/p105 was used as the substrate for determining the kinase activity associated with cyclins D1 and D3. Otherwise, histone H1 was used as the substrate. Kinase assays were performed as described (43) and were repeated at least three times, giving an interassay SD of 10% after normalization of the protein amount.

Luciferase Assays.
HJC12 and HJC{Delta}5 cells were plated at a density of 1 x 106 cells/dish in 10-cm diameter dishes in the presence or absence of 2 µg/ml tetracycline. Cells were transfected 24 h later by the standard calcium phosphate precipitate method as described (24) with 5 µg of the pCE (-543/+263) and pCE (-94/+263) plasmids containing the indicated regions of the murine cyclin E promoter linked to the luciferase reporter gene (44) and the CycA (-89/+11) plasmid containing the indicated regions of the human cyclin A promoter (45) . Each of the above constructs was cotransfected with 1 µg of CMV-lacZ to normalize the efficiency of transfection by ß-galactosidase assay. Cells were harvested 48 h after transfection, and luciferase activity was assayed using the luciferase kit assay according to the manufacture’s instructions (Promega, Madison, WI) and measured using a luminometer (Corning Costar Corp., Cambridge, MA).

EMSA.
Cellular lysates were prepared as for immunoprecipitation, and 10 µg of protein were used for EMSA with the oligonucleotides for the E2F site of the E2 promoter as described previously (46) . E2F complexes containing pRb2/p130 were supershifted by incubating the reaction with the specific pRb2/p130 polyclonal antibody C-20 (Santa Cruz, CA) or the specific E2F4 polyclonal antibody (Santa Cruz, CA).


   RESULTS AND DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
REFERENCES
 
pRb2/p130 Induction Specifically Inhibits Cdk2-associated Kinases in Vivo.
The effects of pRb2/p130 induction on cyclin-dependent kinase activity were examined first to determine if pRb2/p130 acts as a kinase inhibitor in vivo. As shown in Fig. 1Citation (row 1), withdrawal of tetracycline dramatically increased the expression of pRb2/p130 in the HJC12 cells. This led to a substantial reduction in the pRb2/p130-associated histone H1 kinase activity (Fig. 1Citation , row 2). We next examined the associated kinase activity of specific cyclins. Upon induction of pRb2/p130 expression, the kinase activity associated to cyclin A and cyclin E was greatly reduced by 21.6- and 6.8-fold, respectively (Fig. 1Citation , rows 3 and 4). This affect was specific to cyclins A and E and was not attributable to a general inhibition of all cyclin-dependent kinase activity because the associated kinase activity of cyclin D1 actually increased >2-fold upon pRb2/p130 induction (Fig. 1Citation , row 5). The kinase activity associated with cyclin D3 also increased somewhat (Fig. 1Citation , row 6).



View larger version (32K):
[in this window]
[in a new window]
  		Fig. 1. The effects of pRb2/p130 induction on cyclin-dependent kinase activity in vivo (row 1) WB analysis of HJC12 total cell extracts [with (+) or without (-) tetracycline; not induced/induced, respectively] demonstrating a 160-fold increase in the pRb2/p130 protein level upon induction [without (-) tetracycline for 48 h]. The effects of pRb2/p130 induction (- tetracycline) on the following proteins’ associated kinase activity in the same cell extracts: row 2, pRb2/p130-associated kinase activity; row 3, cyclin A-associated kinase activity; row 4, cyclin E-associated kinase activity; row 5, cyclin bD1-associated kinase activity; row 6, D3-associated kinase activity; row 7 (background), NRS-associated kinase activity. row 8, WB analysis with anti-Cdk2, demonstrating that the amount of Cdk2 remains the same in the HJC12 cells in the induced and uninduced states. pRb/p105 was used as the substrate for determining the kinase activity associated with cyclins D1 and D3. Otherwise, histone H1 was used as the substrate.

 
Because coexpression of both cyclin D1 and cyclin D3 with pRb2/p130 rescues pRb2/p130-mediated growth suppression (19) , this increase in activity may be attributable to pRb2/p130 serving as a substrate for the D-type-associated kinases. This is also supported by the finding that pRb2/p130 associates with cyclin D3, and the variation in the phosphorylation status of pRb2/p130 correlates with the maximal activation of cyclin D3-associated kinase activity (14) . The background kinase activity was determined by assaying the kinase activity associated with immunoprecipitations using NRS, as shown in Fig. 1Citation (row 7). Because both cyclin A and cyclin E associate with Cdk2 and the D-type cyclins associate with Cdk4, one explanation may be that Cdk2 kinases may use pRb2/p130 as a substrate and the induction of pRb2/p130 decreases its associated kinase activity because of substrate competition. This was, however, not the case because the amount of Cdk2 associated with pRb2/p130 was the same in the induced and uninduced states as determined by immunoprecipitation with anti-pRb2/p130 polyclonal antibody and Western blotting with anti-Cdk2 polyclonal antibody (Fig. 1Citation , row 8). Additionally, the fact that pRb2/p130 induction decreased cyclin A- and cyclin E-associated kinase activity refuted the notion that the reduction in pRb2/p130-associated kinase activity was caused by mere substrate competition. The fact that both cyclin A and cyclin E are able to rescue pRb2/p130-mediated cell cycle arrest suggests that the inhibition of cyclin A- and cyclin E-associated kinase activity are important events for the biological function of pRb2/p130 (19) . These experiments effectively demonstrated that induction of pRb2/p130 expression specifically inhibits Cdk2-associated kinase activity in vivo.

pRb2/p130 Down-Regulates Cyclin A and E2F1 but Induces p27Kip1 and Cyclin E Expression.
We next decided to examine the effects of pRb2/p130 induction on the expression of a number of key members of the cell cycle machinery by WB analysis as shown in Fig. 2Citation . The parental control cell line HJC{Delta}5 was included to demonstrate that the effects were specific to increased levels of pRb2/p130 and not caused by the Vp16 tet transactivator. Induction of pRb2/p130 expression led to dramatic decreases in the expression of both cyclin A and the transcription factor E2F-1.



View larger version (33K):
[in this window]
[in a new window]
  		Fig. 2. The effects of pRb2/p130 induction on the expression of a number of key members of the cell cycle machinery. Top ordinates, cell lines (HJC{Delta}5 and HJC12 cells) and growth conditions (+ or - tetracycline in the medium, not induced/induced, respectively). Left ordinates, antibodies used in WB assays. Protein levels were tested by Bradford assay and normalized by Coomassie blue staining.

 
E2F-1 expression was sensitive to even the small amount of leak of pRb2/p130 expression in this batch of cell lysates. E2F-1 protein levels were further reduced with higher pRb2/p130 expression levels. The inhibition of cyclin A expression may explain in part the vast reduction in cyclin A-associated kinase activity. Intriguingly, induction of pRb2/p130 expression also led to a substantial induction in the protein levels of the cyclin/Cdk complex inhibitor, p27Kip1. p27Kip1 is a universal Cdk inhibitor that can bind to D-, E-, and A-type cyclin/Cdk complexes and inhibit their activity to regulate G1 progression (47, 48, 49) . This phenomenon also may play a role in the inhibition of Cdk2 kinase activity observed upon pRb2/p130 induction. Conversely, because p27Kip1 levels are mainly regulated by ubiquitin-mediated proteasome degradation that is targeted by cyclin E-Cdk2 phosphorylation of p27Kip1 on T187 (50, 51, 52) , pRb2/p130 through inhibition of cyclin E-associated kinase activity may induce p27Kip1 levels by decreasing or inhibiting targeted proteolysis of p27Kip1. In this manner, pRb2/p130-mediated inhibition of Cdk2-associated kinase activity leads to a positive feedback loop by inducing p27Kip1 levels that can go on to further inhibit Cdk activity, ensuring that pRb2/p130 does not become the substrate of other Cdks and inactivated by phosphorylation.

JCV TAg Binds p27Kip1.
Because the E1A oncoprotein has been previously shown to bind the p27Kip1 protein directly (53) , we decided to examine whether or not JCV TAg is also able to associate with p27Kip1. We performed a series of immunoprecipitations of HJC{Delta}5 and HJC12 cells in both the uninduced (+ tetracycline) and induced states (- tetracycline) with NRS as a negative control, with an anti-p27Kip1 polyclonal antibody, and with the PAB 416 monoclonal antibody that recognizes JCV TAg. The immunoprecipitations underwent electrophoresis on a 10% polyacrylamide SDS gel and were Western-blotted with the PAB 416 anti-TAg monoclonal antibody. In both cell lines in both the uninduced and induced states, p27Kip1 was found associated to JCV TAg, as shown in Fig. 3Citation . This is the first time that JCV TAg has been reported to associate with p27Kip1. Interestingly, induction of pRb2/p130 decreased the amount of p27Kip1 associated to JCV TAg. This implies that pRb2/p130 and p27Kip1 may compete for the same binding site on JCV TAg. The binding of pRb2/p130 and p27Kip1 to JCV TAg may be mutually exclusive via physical hindrance or the induction of a conformational change. However, this may be an affect of an alteration in the phosphorylation pattern of p27Kip1 and/or JCV TAg because of pRb2/p130-mediated inhibition of cyclin A- and E-associated kinase activity.



View larger version (15K):
[in this window]
[in a new window]
  		Fig. 3. In vivo interaction between JCV TAg and p27Kip1 is competed by pRb2/p130. Top ordinates, antibodies [NRS, rabbit polyclonal anti-p27 antibody ({alpha}-p27), and PAB 416], cell lines (HJC{Delta}5 and HJC12 cells), and growth conditions [(+) in the presence of tetracycline, not induced; or (-) without tetracycline, induced] used for immunoprecipitation. Immunoprecipitates underwent electrophoresis on a 10% polyacrylamide SDS gel and were Western-blotted with the PAB 416 anti-TAg monoclonal antibody.

 
One explanation of the induction of p27Kip1 levels by pRb2/p130 may be that JCV TAg targets p27Kip1 for degradation and that the increase in pRb2/p130 levels by competing with p27Kip1 for binding to JCV TAg leads to the increase in p27Kip1. This is unlikely, however, because p27Kip1 is readily detectable and expressed at a substantial level in both the HJC{Delta}5 and HJC12 cells in both the uninduced and induced states (Fig. 3Citation ). More than likely, JCV TAg targets p27Kip1 and inhibits its Cdk-inhibitory activity through sequestering p27Kip1 in much the same manner as E1A inhibits p27Kip1 function (53) . This may also explain why cyclin D1- and D3-associated kinase activity was not down-regulated but actually increased, although p27Kip1 was induced because the induced p27Kip1 may have been sequestered and functionally inactivated by the presence of JCV TAg.

pRb2/p130 and p27Kip1 Interact in Vivo.
An alternative explanation may be that p27Kip1 and pRb2/p130 form a complex that prevents JCV TAg from binding p27Kip1. To test this, we performed a series of immunoprecipitations in HJC12 cells in the uninduced (+ tetracycline) and induced (- tetracycline) states as well as in human osteosarcoma SAOS-2- and SV40-transformed COS7 cells. Immunoprecipitation with anti-pRb2/p130 polyclonal antibody and Western bolt with anti-p27Kip1 polyclonal antibody detected a specific association between pRb2/130 and p27Kip1 that was independent of the presence or absence of SV40 or JCV TAg (Fig. 4Citation ). The association between pRb2/p130 and p27Kip1 was also detected by immunoprecipitation/WB with anti-p27Kip1 and anti-pRb2/p130 antibodies, respectively (data not shown). Because the same amount of p27Kip1 is found in association with pRb2/p130 in both the induced and uninduced states, this suggests that the interaction may be indirect and require the presence of another rate-limiting molecule unaffected by pRb2/p130 induction. pRb2/p130 bound to p27Kip1 may also be part of a complex that inhibits proteasome-mediated degradation of p27Kip1. This, moreover, negates the aforementioned notion that the reduction of p27Kip1 associated with JCV TAg after induction of pRb2/p130 (Fig. 3Citation ) was a result of pRb2/p130 sequestering p27Kip1 via a competition between pRb/p130 and JCV TAg for binding p27Kip1.



View larger version (29K):
[in this window]
[in a new window]
  		Fig. 4. In vivo interaction between pRb2/p130 and p27Kip1. Immunoprecipitation of Cos7, Saos-2, and HJC12 cells grown in the presence (+) or absence (-) of tetracycline with anti-pRb2/p130 polyclonal antibody or NRS (as a negative control) and WB analysis with p27 polyclonal antibody. Arrow, the p27 band indicating a specific association between pRb2/p130 and p27 in all three cell lines as well as in the not induced (+) and induced (-) states of the HJC12 cell line.

 
Enhanced E2F-binding Capacity and pRb2/p130 Growth Inhibition.
Because the growth suppressive function of the Rb family of proteins is thought to occur at least in part by their binding and negative regulation of specific members of the E2F family of transcription factors, we analyzed the status of E2F complexes after induction of pRb2/p130 expression. We performed a series of gel shift assays of HJC12 cells in both the uninduced (+ tetracycline) and induced states (- tetracycline).

By EMSA using an oligonucleotide probe of the E2F DNA-binding sequence labeled with 32P, we detected an E2F complex that was effectively competed with cold wild-type oligonucleotide but not with a point mutant oligonucleotide that abrogates E2F binding to DNA (Fig. 5Citation , Lanes 1 and 2); therefore, these bands were specific. The band of the E2F complex was supershifted by incubation with an antibody that specifically recognizes pRb2/p130 (Fig. 5Citation , Lanes 5 and 8) as well as by an antibody that specifically recognizes E2F4 (Fig. 5Citation , Lanes 4 and 7) in HJC12 cells in the presence or absence of tetracycline. Almost the entire E2F complex was shifted in the HJC12 cells in the induced state (- tetracycline) by incubation of the pRb2/p130 antibody (Fig. 5Citation , Lane 8), indicating that most of the E2F is bound by pRb2/p130 in these cells. However, in the HJC12 cells in the uninduced state (+ tetracycline), only a small fraction of the E2F complex was supershifted by the pRb2/p130 antibody (Fig. 5Citation , Lane 5), a reflection of the low endogenous expression level of pRb2/p130 in the proliferating HJC12 cells (Figs. 1Citation , 2Citation , and 5Citation ).



View larger version (74K):
[in this window]
[in a new window]
  		Fig. 5. The effect of pRb2/p130 induction on E2F-binding capacity. EMSA of HJC12 cells in the induced (- tetracycline, for 48 h) or uninduced (+ tetracycline) status using a 32P-end-labeled double-stranded oligonucleotide of the consensus E2F DNA-binding site as a probe, which was competed with cold wild-type and mutant double-stranded oligonucleotides as indicated to show the specificity of the bands. Incubation of the extracts with an anti-pRb2/p130 antibody as indicated demonstrated the presence of pRb2/p130 in the E2F complexes (Lanes 5 and 8). Incubation of the extracts with an anti-E2F4 antibody as indicated demonstrated the presence of E2F4 in the E2F complexes (Lanes 4 and 7).

 
We have shown previously by flow cytometry analysis (fluorescence-activated cell-sorting analysis) that upon induction of pRb2/p130 expression (HJC 12 - tetracycline), nearly 90% of the cells are found in the G0/G1 stage corresponding to a mean increase of 41.6% in the G0/G1 population (95% confidence intervals, 40.1–43.1%) in three separate experiments. This effect was specific for pRb2/p130 expression because withdrawal of tetracycline from the HJC{Delta}5 parental cell line did not affect their cell cycle distribution, and there was no statistically significant difference between the cell cycle distribution profile of HJC{Delta}5 cells (+ or - tetracycline) and the HJC12 cells in the uninduced state (27) . This, along with the results in Fig. 5Citation , suggest that induction of pRb2/p130 expression in the HJC12 cells provided an abundance of pRb2/p130 that could effectively sequester E2F activity, thereby leading to growth arrest. Therefore, the ability of induced levels of pRb2/p130 to block proliferation correlated with its E2F-binding capacity.

Transcriptional Repression by pRb2/p130 Induction.
Because cyclin A and E2F-1 both contain E2F sites in their promoter regions, their down-regulation may have been caused by pRb2/p130 repression of E2F-mediated transcription (44 , 54) . We first demonstrated that the down-regulation of cyclin A by pRb2/p130 functioned at the transcriptional level because others have previously reported that the E2F-1 promoter linked to a CAT reporter gene is effectively down-regulated by transfection with a pRb2/p130 expression plasmid (6) . HJC12 cells were transfected with the minimal region of the cyclin A promoter (-89/+11), which contains two E2F binding sites and displays the same cell cycle regulation profile as the 7.5-kb full promoter construct (54) , linked to a luciferase reporter gene. Cells were then placed in the presence or the absence of tetracycline for 48 h. As shown in Fig. 6Citation , induction of pRb2/p130 expression greatly inhibited luciferase activity by a >3.2 fold reduction; therefore, increased pRb2/p130 levels silenced expression from the cyclin A minimal promoter. This is in agreement with previous transfection studies demonstrating that histone deacetylase 1 enhances the ability of pRb2/p130 to inhibit E2F-dependent transcription from the cyclin A promoter (55) .



View larger version (27K):
[in this window]
[in a new window]
  		Fig. 6. Luciferase assay of the cyclin A (-89/+11), cyclin E (-94/+263), and cyclin E (-543/+263) promoter HJC12 cells induced (- tetracycline, for 48 h) or not induced (+ tetracycline). Induction of pRb2/p130 expression greatly inhibited the luciferase activity of the cyclin A minimal promoter (-89/+11 promoter region) by >3.2-fold (column 4) and by 4.2-fold that of the minimal cyclin E promoter (-94/+263 promoter region). Transcription from the -543/+263 cyclin E promoter region was enhanced by 1.8-fold upon pRb2/p130 expression (column 8). The graph represents the mean of three separate experiments each performed in triplicate with error bars included.

 
Transcription from the minimal cyclin E promoter (-94/+263 promoter region) linked to a luciferase reporter gene was repressed by 4.2-fold upon pRb2/p130 induction (Fig. 6Citation ). This region contains an E2F-binding site that has previously been shown by mutational analysis to be required for G1-specific activation of the cyclin E promoter (44) . This fits the predicted model of pRb2/p130 repression of E2F-mediated transcription.

Unexpectedly, transcription from the -543/+263 cyclin E promoter region linked to a luciferase reporter gene was enhanced by 1.8-fold upon pRb2/p130 expression (Fig. 6Citation ). This 806-bp fragment has been shown to retain full promoter activity and the cell cycle regulation of the promoter. In our system, the -94/+263 promoter region exhibited ~50% of the promoter activity of the -543/+263 construct in the uninduced state, which is consistent with previously published data (44) . Additionally, our work supports the notion that there are additional potential E2F-binding sites as well as other regulatory sites within this 806-bp region that are functionally different from the E2F site within the -94/+263 region (44) . This was concordant with the protein levels of cyclin E in HJC12 cells in the induced and uninduced states (Fig. 2Citation ). Upon withdrawal of tetracycline from HJC12 cells, the Mr 50,000 and 42,000 forms of cyclin E continued to increase as the levels of pRb2/p130 accumulated over time (Fig. 7Citation ). Pulse chase experiments using HJC12 cells (± tetracycline) revealed that the half-life of cyclin E was greatly extended to beyond 48 h upon pRb2/p130 induction.4 We presently cannot explain this occurrence. We can only hypothesize that protein levels of cyclin E must remain high in the presence of pRb2/p130 expression because cyclin E-associated kinase activity is hypothesized to be the rate-limiting factor involved in the G1-S transition (56 , 57) . In this manner, cyclin E is present to serve as an early immediate response gene when the cell is signaled to divide. Both pRb2/p130 and cyclin E may exhibit negative feedback regulation of each other. Cyclin E expression may be maintained by pRb2/p130-mediated induction at the transcriptional level (as shown here) and possibly by stabilizing the short half-life of the cyclin E protein thought to be mediated by its PEST sequences (58 , 59) . Cyclin E is maintained in an inactive form by pRb2/p130 inhibition of cyclin E-associated kinase activity both directly and by induction of the universal CDK inhibitor p27Kip1. Then as the cell prepares for DNA replication, pRb2/p130 is inactivated most likely by phosphorylation, thus releasing its inhibition on cyclin E-Cdk2 kinase activity, which may now enhance pRb2/p130 phosphorylation and inactivation as well as the phosphorylation and degradation of p27Kip1 allowing the cell to progress through the G1-S phase transition. Then cyclin E is rapidly degraded without the induction and/or protection of pRb2/p130, thus preventing endoreduplication, maintaining DNA fidelity, and allowing the cycle to renew (60) . Fig. 8Citation is a graphic depiction of our hypothesized model of the negative feedback regulatory loop involving pRb2/p130, p27Kip1, and cyclin E.



View larger version (22K):
[in this window]
[in a new window]
  		Fig. 7. Steady accumulation of cyclin E protein with increasing levels of pRb2/p130 expression. Time-course WB analysis of cyclin E protein levels in HJC12 cells after induction of pRb2/p130 expression using an anticyclin E polyclonal antibody (Santa Cruz). The cells were harvested at the indicated minutes after withdrawal from tetracycline. Arrows, the steady accumulation of the Mr 42,000 and 50,000 isoforms of cyclin E. Total cell extracts were electrophoresed on a 10% SDS polyacrylamide gel.

 


View larger version (28K):
[in this window]
[in a new window]
  		Fig. 8. Hypothesized model of the cooperation between pRb2/p130 and p27Kip1 in regulating cellular proliferation and their proposed involvement in a negative feedback regulatory loop with cyclin E. Thickened arrows, the effects of RB2/p130 induction on the normal progression (thin arrows) of the cell cycle. X, an unidentified molecule that may facilitate the pRb2/p130 interaction with p27Kip1. The enzymatic mediators and modulators are indicated for each step next to the arrow indicating their influence on the equilibrium of the reaction. A detailed explanation is provided in the "Results and Discussion" section.

 
Induction of the -543/+263 cyclin E promoter region demonstrates that the reduction in the expression of the cyclin A promoter was specific to pRb2/p130 expression and not merely attributable to the cells being in a growth-arrested state. These same assays were also performed in the HJC{Delta}5 cells, and no significant effects upon luciferase activity were seen with any of the promoter constructs in the presence or absence of tetracycline (data not shown). Therefore, the effects were specific to pRb2/p130 induction.

The down-regulation of the cyclin A promoter by pRb2/p130 may not only be attributable to pRb2/p130 sequestering E2F activity, but it may also be attributable to the induction of p27Kip1 expression by pRb2/p130. Others have previously demonstrated that p27Kip1 inhibits the expression of E2F-regulated genes, specifically the cyclin A and cyclin E genes, by inducing the accumulation of repressor complexes of E2F (61) . The fact that pRb2/p130 induction down-regulates the cyclin A promoter but induces the cyclin E promoter may be a reflection of the presence of JCV TAg in the experimental system. Repression of the cyclin E promoter may be more dependent upon the presence of p27Kip1 Cdk-inhibitory activity that may be effectively sequestered by JCV TAg.

Our results indicate that pRb2/p130 elicits growth suppression by impacting upon multiple molecular pathways. Induction of pRb2/p130 does specifically inhibit cyclin A- and cyclin E-associated kinase activity in vivo. This evidence confirms previous in vitro data that demonstrated a p21-like kinase inhibitory domain within the amino terminus of p107 and pRb2/p130 as well as a second kinase inhibitory domain found only within the spacer region of pRb2/p130, which inhibited Cdk2 kinase activity (21, 22, 23) . However, in vivo the scenario is not this straight forward. pRb2/p130 also increases the protein level of the Cdk inhibitor p27Kip1. Because p27Kip1 is a universal Cdk inhibitor, this may provide a positive feedback loop for enhancing the growth regulatory function of pRb2/p130. By inhibition of cyclin E-Cdk2 kinase activity, pRb2/p130 may prevent p27Kip1 from being targeted for ubiquitin-mediated proteasome degradation. In turn, p27Kip1 can inhibit the function of several Cdks (62) , thus blocking the phosphorylation and functional inactivation of the Rb family proteins. The down-regulation of cyclin A expression by induction of pRb2/p130 would further inhibit Cdk2 kinase activity. Additionally, the repression of E2F-regulated complexes by pRb2/p130 and p27Kip1 further links the growth regulatory functions of these two proteins.

The demonstration that JCV TAg associates with p27Kip1 further testifies to the importance of this protein in regulating normal cell division. JCV TAg much like E1A may sequester p27Kip1 function. Alternatively, TAg may use its association with p27Kip1 to alter the phosphorylation state of pRb2/p130 and p107 because SV40 and BK virus TAgs have been shown to alter the phosphorylation states of p107 and pRb2/p130 and to decrease the half-life of pRb2/p130 (63, 64, 65) . If pRb2/p130 and p27Kip1 were competing for the same binding site on JCV TAg, that would decrease the likelihood of such a scenario. However, increased degradation of pRb2/p130 mediated by TAg would free more TAg to bind and sequester the activity of p27Kip1. The fact that two DNA tumor viruses simultaneously evolved a mechanism to target the Rb family proteins and p27Kip1 (27 , 30, 31, 32, 33 , 53) further supports a functional link between the Rb family, specifically pRb2/p130, and p27Kip1.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by the "Sbarro Institute for Cancer Research and Molecular Medicine," NIH Grant RO1 CA 60999-01A1, Grant PO1 NS 36466 (to A. G.), and NIH Grant 1PO1 NS36466 (to K. K. and A. G.). P. P. C. is the recipient of a fellowship from the "Associazione Leonardo di Capua," (Napoli, Italy). A. D. L. is financed by FIRC grants in Italy. Back

2 To whom requests for reprints should be addressed, at Department of Pathology, Anatomy & Cell Biology, Jefferson Medical College, 1020 Locust Street, Philadelphia, Pennsylvania, 19107. Phone: (215) 503-0781; Fax: (215) 923-9626; E-mail: agiordan{at}lac.jci.tju.edu Back

3 The abbreviations used are: Rb, retinoblastoma; TAg, T antigen; Tetp, tetracycline promoter; EMSA, electrophoretic mobility shift assay; WB, Western blot; NRS, normal rabbit serum. Back

4 manuscript in preparation. Back

Received 11/30/99. Accepted 3/20/99.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS AND DISCUSSION
 REFERENCES
 

  1. Paggi M. G., Baldi A., Bonetto F., Giordano A. Retinoblastoma protein family in cell cycle and cancer: a review. J. Cell. Biochem., 62: 418-430, 1996.[Medline]
  2. Stiegler P., Kasten M., Giordano A. The RB family of Cell Cycle Regulatory Factors. J. Cell. Biochem., 30/31: 30-36, 1998.
  3. Slansky J. E., Farnham P. J. Introduction to the E2F family: protein structure and gene regulation. Curr. Top. Microbiol. Immunol., 208: 1-30, 1996.[Medline]
  4. Cobrinik D., Whyte P., Peeper D. S., Jacks T., Weinberg R. A. Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev., 7: 2392-2404, 1993.[Abstract/Free Full Text]
  5. Moberg K., Starz M. A., Lees J. A. E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry. Mol. Cell. Biol., 16: 1436-1449, 1996.[Abstract]
  6. Johnson D. G. Regulation of E2F-1 gene expression by p130 (Rb2) and D-type cyclin kinase activity. Oncogene, 11: 1685-1692, 1995.[Medline]
  7. Zhu L., Xie E., Chang L. S. Differential roles of two tandem E2F sites in repression of the human p107 promoter by retinoblastoma and p107 proteins. Mol. Cell. Biol., 15: 3552-3562, 1995.[Abstract]
  8. Chellappan S. P. The E2F transcription factor: role in cell cycle regulation and differentiation. Mol. Cell. Differ., 2: 201-220, 1994.
  9. Ginsberg D., Vairo G., Chittenden T., Xiao Z. X., Xu G., Wydner K. L., DeCaprio J. A., Lawrence J. B., Livingston D. M. E2F-4, a new member of the E2F transcription factor family, interacts with p107. Genes Dev., 8: 2665-2679, 1994.[Abstract/Free Full Text]
  10. Beijersbergen R. L., Kerkhoven R. M., Zhu L., Carlee L., Voorhoeve P. M., Bernards R. E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo. Genes Dev., 8: 2680-2690, 1994.[Abstract/Free Full Text]
  11. Hijmans E. M., Voorhoeve P. M., Beijersbergen R. L., van ’t Veer L. J., Bernards R. E2F-5, a new E2F family member that interacts with p130 in vivo. . Mol. Cell. Biol., 15: 3082-3089, 1995.[Abstract]
  12. Chittenden T., Livingston D. M., DeCaprio J. A. Cell cycle analysis of E2F in primary human T cells reveals novel E2F complexes and biochemically distinct forms of free E2F, Mol. Cell. Biol., 13: 3975-3983, 1993.
  13. Beijersbergen R. L., Carlee L., Kerkhoven R. M., Bernards R. Regulation of the retinoblastoma protein-related p107 by G1 cyclin complexes. Genes Dev., 9: 1340-1353, 1995.[Abstract/Free Full Text]
  14. Dong F., Cress W. D., Jr., Agrawal D., Pledger W. J. The role of cyclin D3-dependent kinase in the phosphorylation of p130 in mouse BALB/c 3T3 fibroblasts. . J. Biol. Chem., 273: 6190-6195, 1998.[Abstract/Free Full Text]
  15. Ewen M. E., Faha B., Harlow E., Livingston D. M. Interaction of p107 with cyclin A independent of complex formation with viral oncoproteins. Science (Washington DC)., 255: 85-87, 1992.[Abstract/Free Full Text]
  16. Faha B., Ewen M. E., Tsai L. H., Livingston D. M., Harlow E. Interaction between human cyclin A and adenovirus E1A-associated p107 protein. Science (Washington DC), 255: 87-90, 1992.[Abstract/Free Full Text]
  17. Li Y., Graham C., Lacy S., Duncan A. M., Whyte P. The adenovirus E1A-associated 130-kD protein is encoded by a member of the retinoblastoma gene family and physically interacts with cyclins A and E. Genes Dev., 7: 2366-2377, 1993.[Abstract/Free Full Text]
  18. Hannon G. J., Demetrick D., Beach D. Isolation of the Rb-related p130 through its interaction with CDK2 and cyclins. Genes Dev., 7: 2378-2391, 1993.[Abstract/Free Full Text]
  19. Claudio P. P., De Luca A., Howard C. M., Baldi A., Firpo E. J., Koff A., Paggi M. G., Giordano A. Functional analysis of pRb2/p130 interaction with cyclins. Cancer Res., 56: 2003-2008, 1996.[Abstract/Free Full Text]
  20. Zhu L., van den Heuvel S., Helin K., Fattaey A., Ewen M., Livingston D., Dyson N., Harlow E. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev., 7: 1111-1125, 1993.[Abstract/Free Full Text]
  21. Zhu L., Harlow E., Dynlacht B. D. p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F. Genes Dev., 9: 1740-1752, 1995.[Abstract/Free Full Text]
  22. Woo M. S., Sanchez I., Dynlacht B. D. p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity. Mol. Cell. Biol., 17: 3566-3579, 1997.[Abstract]
  23. De Luca A., MacLachlan T. K., Bagella L., Dean C., Howard C. M., Claudio P. P., Baldi A., Khalili K., Giordano A. A unique domain of pRb2/p130 acts as an inhibitor of Cdk2 kinase activity. J. Biol. Chem., 272: 20971-20974, 1997.[Abstract/Free Full Text]
  24. Claudio P. P., Howard C. M., Baldi A., De Luca A., Fu Y., Condorelli G., Sun Y., Colburn N., Calabretta B., Giordano A. p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res., 54: 5556-5560, 1994.[Abstract/Free Full Text]
  25. Hinds P. W., Mittnacht S., Dulic V., Arnold A., Reed S. I., Weinberg R. A. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell, 70: 993-1006, 1992.[Medline]
  26. Lacy S., Whyte P. Identification of a p130 domain mediating interactions with cyclin A/cdk 2 and cyclin E/cdk 2 complexes. Oncogene, 14: 2395-2406, 1997.[Medline]
  27. Howard C. M., Claudio P. P., Gallia G. L., Gordon J., Giordano G. G., Hauck W. W., Khalili K., Giordano A. Retinoblastoma-related protein pRb2/p130 and suppression of tumor growth in vivo. J. Natl. Cancer Inst., 90: 1451-1460, 1998.[Abstract/Free Full Text]
  28. Frisque, R. J., and White, F. A. The Molecular Biology of JC Virus, Causative Agent of Progressive Multifocal Leukoencephalopathy. Molecular Neurovirology, pp. 25–158. Towana, NJ: Roos RP, 1992.
  29. Pipas J. M. Common and unique features of T antigens encoded by the polyomavirus grou. p. J. Virol., 66: 3979-3985, 1992.[Abstract/Free Full Text]
  30. Haggerty S., Walker D. L., Frisque R. J. JC virus-simian virus 40 genomes containing heterologous regulatory signals and chimeric early regions: identification of regions restricting transformation by JC virus. J. Virol., 63: 2180-2190, 1989.[Abstract/Free Full Text]
  31. Bollag B., Chuke W. F., Frisque R. J. Hybrid genomes of the polyomaviruses JC virus, BK virus, and simian virus 40: identification of sequences important for efficient transformation. J. Virol., 63: 863-872, 1989.[Abstract/Free Full Text]
  32. Dyson N., Bernards R., Friend S. H., Gooding L. R., Hassell J. A., Major E. O., Pipas J. M., Vandyke T., Harlow E. Large T antigens of many polyomaviruses are able to form complexes with the retinoblastoma protein. J. Virol., 64: 1353-1356, 1990.[Abstract/Free Full Text]
  33. Dyson N., Howley P. M., Munger K., Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science (Washington DC), 243: 934-937, 1989.[Abstract/Free Full Text]
  34. Helin K., Holm K., Niebuhr A., Eiberg H., Tommerup N., Hougaard S., Poulsen H. S., Spang-Thomsen M., Norgaard P. Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc. Natl. Acad. Sci. USA, 94: 6933-6938, 1997.[Abstract/Free Full Text]
  35. Claudio P. P., Howard C. M., Pacilio C., Cinti C., Romano G., Minimo C., Maraldi N. M., Minna J. D., Gelbert L., Leoncini L., Tosi G. M., Hicheli P., Caputi M., Giordano G. G., Giordano A. Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. Cancer Res., 60: 372-382, 2000.[Abstract/Free Full Text]
  36. De Luca A., Baldi A., Esposito V., Howard C. M., Bagella L., Rizzo P., Caputi M., Pass H. I., Giordano G. G., Baldi F., Carbone M., Giordano A. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas [see comments]. Nat. Med., 3: 913-916, 1997.[Medline]
  37. Claudio P. P., Howard C. M., Fu Y., Cinti C., Califano L., Micheli P., Mercer E. W., Caputi M., Giordano A. Mutations in the retinoblastoma-related gene RB2/p130 in primary nasopharyngeal carcinoma. Cancer Res., 60: 8-12, 2000.[Abstract/Free Full Text]
  38. Cinti C., Claudio P. P., Howard C. M., Neri L. M., Fu Y., Leoncini L., Tosi G. M., Maraldi N. M., Giordano A. Genetic alterations disrupting the nuclear localization of the retinoblastoma-related gene RB2/p130 in human tumor cell lines and primary tumors. Cancer Res., 60: 383-389, 2000.[Abstract/Free Full Text]
  39. Cinti C., Leoncini L., Nyongo A., Ferrari F., Lazzi S., Bellan C., Vatti R., Zamparelli A., Cevenini G., Tosi G. M., Claudio P. P., Maraldi N. M., Tosi P., Giordano A. Genetic Alterations of the Retinoblastoma-Related Gene RB2/p130 Identify Different Pathogenetic Mechanisms in and among Burkitt’s Lymphoma Subtypes. Am. J. Pathol., 156: 751-760, 2000.[Abstract/Free Full Text]
  40. Raj G. V., Gordon J., Logan T. J., Hall D. J., De Luca A., Giordano A., Khalili K. Characterization of glioma cells derived from human polyomavirus-induced brain tumors in hamsters. Int. J. Oncol., 7: 801-808, 1995.
  41. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA, 89: 5547-5551, 1992.[Abstract/Free Full Text]
  42. Baldi A., De Luca A., Claudio P. P., Baldi F., Giordano G. G., Tommasino M., Paggi M. G., Giordano A. The RB2/p130 gene product is a nuclear protein whose phosphorylation is cell cycle regulated. J. Cell. Biochem., 59: 402-408, 1995.[Medline]
  43. Giordano A., Lee J. H., Scheppler J. A., Herrmann C., Harlow E., Deuschle U., Beach D., Franza B. R., Jr. Cell cycle regulation of histone H1 kinase activity associated with the adenoviral protein E1A. Science, 253: 1271-1275, 1991.[Abstract/Free Full Text]
  44. Botz J., Zerfass-Thome K., Spitkovsky D., Delius H., Vogt B., Eilers M., Hatzigeorgiou A., Jansen-Durr P. Cell cycle regulation of the murine cyclin E gene depends on an E2F binding site in the promoter. Mol. Cell. Biol., 16: 3401-3409, 1996.[Abstract]
  45. Shulze A., Zerfass-Thome K., Berges J., Middendorp S., Jansen-Durr P., Henglein B. Anchorage-dependent transcription of the cyclin A gene. Mol. Cell. Biol., 16: 4632-4638, 1996.[Abstract]
  46. Pagano M., Draetta G., Jansen-Durr P. Association of cdk2 kinase with the transcription factor E2F during S phase. Science (Washington DC), 255: 1144-1147, 1992.[Abstract/Free Full Text]
  47. Polyak K., Kato J. Y., Solomon M. J., Sherr C. J., Massague J., Roberts J. M., Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev., 8: 9-22, 1994.[Abstract/Free Full Text]
  48. Polyak K., Lee M. H., Erdjument-Bromage H., Koff A., Roberts J. M., Tempst P., Massague J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.[Medline]
  49. Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell, 78: 67-74, 1994.[Medline]
  50. Sheaff R. J., Groudine M., Gordon M., Roberts J. M., Clurman B. E. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev., 11: 1464-1478, 1997.[Abstract/Free Full Text]
  51. Morisaki H., Fujimoto A., Ando A., Nagata Y., Ikeda K., Nakanishi M. Cell cycle-dependent phosphorylation of p27 cyclin-dependent kinase (Cdk) inhibitor by cyclin E/Cdk2. Biochem. Biophys. Res. Commun., 240: 386-390, 1997.[Medline]
  52. Vlach J., Hennecke S., Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J., 16: 5334-5344, 1997.[Medline]
  53. Mal A., Poon R. Y., Howe P. H., Toyoshima H., Hunter T., Harter M. L. Inactivation of p27Kip1 by the viral E1A oncoprotein in TGF ß-treated cells. Nature (Lond.), 380: 262-265, 1996.[Medline]
  54. Schulze A., Zerfass K., Spitkovsky D., Middendorp S., Berges J., Helin K., Jansen-Durr P., Henglein B. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc. Natl. Acad. Sci. USA, 92: 11264-11268, 1995.[Abstract/Free Full Text]
  55. Stiegler P., De Luca A., Bagella L., Giordano A. The COOH-terminal region of pRb2/p130 binds to histone deacetylase 1 (HDAC1), enhancing transcriptional repression of the E2F-dependent cyclin A promoter. Cancer Res., 58: 5049-5052, 1998.[Abstract/Free Full Text]
  56. Koff A., Giordano A., Desai D., Yamashita K., Harper J. W., Elledge S., Nishimoto T., Morgan D. O., Franza B. R., Roberts J. M. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science (Washington DC), 257: 1689-1694, 1992.[Abstract/Free Full Text]
  57. Dulic V., Lees E., Reed S. I. Association of human cyclin E with a periodic G1-S phase. Science (Washington DC), 257: 1958-1961, 1992.[Abstract/Free Full Text]
  58. Lew D. J., Dulic V., Reed S. I. Isolation of three novel human cyclins by rescue of G1 cyclin (CLN) function in yeast. Cell, 66: 1197-1206, 1991.[Medline]
  59. Koff A., Cross F., Fisher A., Schumacher J., Leguellec K., Philippe M., Roberts J. M. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell, 66: 1217-1228, 1991.[Medline]
  60. Spruck C. H., Won K-A., Reed S. I. Deregulated cyclin E induces chromosome instability. Nature (Lond.), 401: 297-300, 1999.[Medline]
  61. Shiyanov P., Hayes S., Chen N., Pestov D. G., Lau L. F., Raychaudhuri P. p27Kip1 induces an accumulation of the repressor complexes of E2F and inhibits expression of the E2F-regulated genes. Mol. Biol. Cell, 8: 1815-1827, 1997.[Abstract]
  62. Masciukko V., Sgambato A., Pacilio C., Pucci B., Ferrandina G., Palazzo J., Carbone A., Cittadini A., Mancuso S., Scambia G., Giordano A. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res., 59: 3790-3794, 1999.[Abstract/Free Full Text]
  63. Stubdal H., Zalvide J., Campbell K. S., Schweitzer C., Roberts T. M., DeCaprio J. A. Inactivation of pRB-related proteins p130 and p107 mediated by the J domain of simian virus 40 large T antigen. Mol. Cell. Biol., 17: 4979-4990, 1997.[Abstract]
  64. Stubdal H., Zalvide J., DeCaprio J. A. Simian virus 40 large T antigen alters the phosphorylation state of the RB-related proteins p130 and p107. J. Virol., 70: 2781-2788, 1996.[Abstract]
  65. Harris K. F., Christensen J. B., Imperiale M. J. BK virus large T antigen: interactions with the retinoblastoma family of tumor suppressor proteins and effects on cellular growth control. J. Virol., 70: 2378-2386, 1996.[Abstract]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
H. W. Yim, H.-S. Jong, T. Y. Kim, H. H. Choi, S. G. Kim, S. H. Song, J. Kim, S.-G. Ko, J. W. Lee, T.-Y. Kim, et al.
Cyclooxygenase-2 Inhibits Novel Ginseng Metabolite-Mediated Apoptosis
Cancer Res., March 1, 2005; 65(5): 1952 - 1960.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. M. Blalock, J. W. Geddes, K. C. Chen, N. M. Porter, W. R. Markesbery, and P. W. Landfield
Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses
PNAS, February 17, 2004; 101(7): 2173 - 2178.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Cortellino, D. Turner, V. Masciullo, F. Schepis, D. Albino, R. Daniel, A. M. Skalka, N. J. Meropol, C. Alberti, L. Larue, et al.
From The Cover: The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity
PNAS, December 9, 2003; 100(25): 15071 - 15076.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. P. Singh, C. Agarwal, and R. Agarwal
Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes
Carcinogenesis, March 1, 2003; 24(3): 555 - 563.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pathol.Home page
C Simone, N Resta, L Bagella, A Giordano, and G Guanti
Cyclin E and chromosome instability in colorectal cancer cell lines
Mol. Pathol., June 1, 2002; 55(3): 200 - 203.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Tyagi, C. Agarwal, and R. Agarwal
Inhibition of Retinoblastoma Protein (Rb) Phosphorylation at Serine Sites and an Increase in Rb-E2F Complex Formation by Silibinin in Androgen-dependent Human Prostate Carcinoma LNCaP Cells: Role in Prostate Cancer Prevention
Mol. Cancer Ther., May 1, 2002; 1(7): 525 - 532.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Tong, D. Xie, J. O'Kelly, C. W. Miller, C. Muller-Tidow, and H. P. Koeffler
Cyr61, a Member of CCN Family, Is a Tumor Suppressor in Non-Small Cell Lung Cancer
J. Biol. Chem., December 7, 2001; 276(50): 47709 - 47714.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)